Biolexis Therapeutics Presents First-in-Human Phase 1a Data for BLX-7006, an Oral Small-Molecule GLP-1 Receptor Agonist with a Structurally Distinct Allosteric Mechanism, at ObesityWeek® 2026
HIGHLIGHTS • Differentiated mechanism: Structural and preclinical studies demonstrate activation through a distinct allosteric binding site and potentiation of endogenous GLP-1 signaling. • Favorable safety & tolerability: BLX-7006 was generally well tolerated at oral doses up to 150 mg,...
Covered in this story
Call it yourself
No calls on $BLX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Banco Latinoamericano de Comercio →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.